Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695).

ABSTRACT:

Background

The COXEN gene expression model was evaluated for prediction of response to neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC).

Objective

To conduct a secondary analysis of the association of each COXEN score with event-free survival (EFS) and overall survival (OS) and by treatment arm.

Design, setting, and participants

This was a randomized phase 2 trial of neoadjuvant gemcitabine-cisplatin (GC) or dose-dense methotrexate-vinblastine-adriamycin-cisplatin (ddMVAC) in MIBC.

Intervention

Patients were randomized to ddMVAC (every 14 d) or GC (every 21 d), both for four cycles.

Outcome measurements and statistical analysis

EFS events were defined as progression or death before scheduled surgery, a decision to not undergo surgery, r

SUBMITTER: Flaig TW 

PROVIDER: S-EPMC10659139 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature